These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10467763)

  • 1. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units.
    D'Aunno T; Vaughn TE; McElroy P
    J Health Soc Behav; 1999 Jun; 40(2):175-92. PubMed ID: 10467763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient substance abuse treatment and HIV prevention: an update.
    Pollack HA; D'Aunno T; Lamar B
    J Subst Abuse Treat; 2006 Jan; 30(1):39-47. PubMed ID: 16377451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isomorphism and external support in conflicting institutional environments: a study of drug abuse treatment units.
    D'Aunno T; Sutton RI; Price RH
    Acad Manage J; 1991 Sep; 34(3):636-61. PubMed ID: 10128668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug abuse treatment as a strategy to prevent human immunodeficiency virus infection among intravenous drug users. How can we maximize prevention of infection?
    West AP
    Arch Intern Med; 1991 Aug; 151(8):1493-6. PubMed ID: 1651688
    [No Abstract]   [Full Text] [Related]  

  • 5. Supervisor ideology and organizational response: HIV/AIDS prevention in outpatient substance abuse treatment units.
    Clapp JD; Burke AC
    Adm Soc Work; 1997; 21(1):49-64. PubMed ID: 10166759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating HIV prevention into substance user treatment: current practices and challenges.
    Mitchell CG; Oltean A
    Subst Use Misuse; 2007; 42(14):2173-82. PubMed ID: 18097998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005.
    Pollack HA; D'Aunno T
    J Subst Abuse Treat; 2010 Jun; 38(4):307-16. PubMed ID: 20171038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do licensing and accreditation matter in outpatient substance abuse treatment programs?
    Wells R; Lemak CH; Alexander JA; Nahra TA; Ye Y; Campbell CI
    J Subst Abuse Treat; 2007 Jul; 33(1):43-50. PubMed ID: 17588488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences.
    Broome KM; Joe GW; Simpson DD
    AIDS Educ Prev; 1999 Aug; 11(4):293-306. PubMed ID: 10494354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health services research: drug use and human immunodeficiency virus in the United States.
    Flanzer J
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S439-44. PubMed ID: 14648461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus prevention and the potential of drug abuse treatment.
    Metzger DS; Navaline H
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S451-6. PubMed ID: 14648463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organizational factors related to AIDS/HIV education in outpatient substance abuse treatment units.
    Clapp JD
    J Health Soc Policy; 1998; 9(3):1-13. PubMed ID: 10174381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of policy in community pharmacies' response to injection-drug use: results of a nationwide Canadian survey.
    Myers T; Cockerill R; Millson M; Rankin J; Worthington C
    AIDS Public Policy J; 1996; 11(2):78-88. PubMed ID: 10915241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.
    Hammett TM; Wu Z; Duc TT; Stephens D; Sullivan S; Liu W; Chen Y; Ngu D; Des Jarlais DC
    Addiction; 2008 Jan; 103(1):137-45. PubMed ID: 18028519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview.
    Bobrova N; Sarang A; Stuikyte R; Lezhentsev K
    Int J Drug Policy; 2007 Aug; 18(4):313-8. PubMed ID: 17689380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
    Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
    Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions.
    Kalichman SC
    Psychosom Med; 2008 Jun; 70(5):593-7. PubMed ID: 18519882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV, drug use, unsafe sex -- bad news.
    Indian Med Trib; 1996 Apr; 4(8):2. PubMed ID: 12179219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.